Ohlsson Lena, Kohan Alison B, Tso Patrick, Ahrén Bo
Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Regul Pept. 2014 Feb 10;189:40-5. doi: 10.1016/j.regpep.2014.02.001. Epub 2014 Feb 28.
Using a newly developed in vivo model measuring glucagon-like peptide-1 (GLP-1) in gut lymphatics in mice, we quantified GLP-1 secretion in vivo after glucose versus fat ingestion with and without concomitant DPP-4 inhibition. The mesenteric lymphatic duct was cannulated in anesthetized C57BL6/J mice and lymph was collected in 30 min intervals. Glucose or fat emulsion (Intralipid®) (0.03, 0.1 or 0.3 kcal) with or without DPP-4-inhibition (NVP DPP728; 10 μmol/kg) was administered by gastric gavage. Basal intact GLP-1 levels were 0.37±0.04 pmol/l (n=61) in lymph compared to 0.07±0.03 in plasma (n=6; P=0.04) and basal DPP-4 activity was 4.7±0.3 pmol/min/μl in lymph (n=23) compared to 22.3±0.9 pmol/min/μl in plasma (n=8; P<0.001). Lymph flow increased from 1.2±0.1 μl/min to 2.3±02μl/min at 30 min after glucose and fat administration, with no difference between type of challenge or dose (n=81). Lymph GLP-1 levels increased calorie-dependently after both glucose and fat but with different time courses in that glucose induced a transient increase which had returned to baseline after 90 min whereas the lipid induced a sustained increase which was still elevated above baseline after 210 min. Lymph GLP-1 appearance during 210 min was two to three-fold higher after glucose (7.4±2.3 fmol at 0.3 kcal) than after isocaloric fat (2.9±0.8 fmol at 0.3 kcal; P<0.001). The slope between caloric load and lymph GLP-1 appearance was, however, identical after glucose and fat. We conclude that lymph GLP-1 is higher than plasma GLP-1 whereas lymph DPP-4 activity is lower than plasma DPP-4 activity and that both glucose and fat clearly stimulate GLP-1 secretion calorie-dependently in vivo but with different time courses.
利用一种新开发的体内模型来测量小鼠肠道淋巴管中的胰高血糖素样肽-1(GLP-1),我们在有或没有同时进行二肽基肽酶-4(DPP-4)抑制的情况下,对摄入葡萄糖和脂肪后体内的GLP-1分泌进行了定量。在麻醉的C57BL6/J小鼠中插入肠系膜淋巴管,并每隔30分钟收集一次淋巴液。通过胃管给予含或不含DPP-4抑制剂(NVP DPP728;10 μmol/kg)的葡萄糖或脂肪乳剂(英脱利匹特®)(0.03、0.1或0.3千卡)。淋巴液中基础完整GLP-1水平为0.37±0.04 pmol/l(n=61),而血浆中为0.07±0.03(n=6;P=0.04);淋巴液中基础DPP-4活性为4.7±0.3 pmol/分钟/微升(n=23),而血浆中为22.3±0.9 pmol/分钟/微升(n=8;P<0.001)。给予葡萄糖和脂肪后30分钟,淋巴液流量从1.2±0.1微升/分钟增加到2.3±0.2微升/分钟,刺激类型或剂量之间无差异(n=81)。葡萄糖和脂肪摄入后,淋巴液中GLP-1水平均呈热量依赖性增加,但时间进程不同,葡萄糖引起短暂增加,90分钟后恢复到基线水平,而脂质引起持续增加,210分钟后仍高于基线水平。在210分钟内,葡萄糖摄入后淋巴液中GLP-1的出现量(0.3千卡时为7.4±2.3 fmol)比等热量脂肪摄入后(0.3千卡时为2.9±0.8 fmol;P<0.001)高两到三倍。然而,葡萄糖和脂肪摄入后热量负荷与淋巴液中GLP-1出现量之间的斜率相同。我们得出结论,淋巴液中GLP-1高于血浆中GLP-1,而淋巴液中DPP-4活性低于血浆中DPP-4活性,并且葡萄糖和脂肪在体内均能明显地以热量依赖性方式刺激GLP-1分泌,但时间进程不同。